GLMD

Galmed Pharmaceuticals Ltd

GLMD, USA

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

https://galmedpharma.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GLMD
stock
GLMD

Galmed Pharmaceuticals’ Aramchol Study: Key Updates and Market Implications TipRanks

Read more →
GLMD
stock
GLMD

Galmed stock rises after patent grant for MASH combo therapy By Investing.com Investing.com South Africa

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

HOLD

Target Price:

$12

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.20

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.16 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.87 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.12

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.42% of the total shares of Galmed Pharmaceuticals Ltd

1.

Morgan Stanley - Brokerage Accounts

(0.6127%)

since

2025/06/30

2.

Schonfeld Strategic Advisors LLC

(0.4233%)

since

2025/06/30

3.

CAMBRIDGE Invest RESEARCH ADVISORS, INC.

(0.1849%)

since

2025/06/30

4.

UBS Group AG

(0.126%)

since

2025/06/30

5.

SBI Securities Co Ltd

(0.0386%)

since

2025/06/30

6.

Macquarie Healthcare I

(0.031%)

since

2025/07/31

7.

Uma Financial Services Inc

(0.0004%)

since

2025/06/30

8.

TSFG, LLC

(0.0003%)

since

2025/03/31

10.

Wells Fargo & Co

(0.0002%)

since

2025/06/30

11.

Advisor Group Holdings, Inc.

(0.0001%)

since

2025/06/30

12.

Hanson Mcclain Inc

(0%)

since

2025/06/30

13.

TD Waterhouse Canada Inc

(0%)

since

2025/06/30

14.

ZRC WEALTH MANAGEMENT, LLC

(0%)

since

2025/06/30

15.

Dogwood Wealth Management LLC

(0%)

since

2025/06/30

16.

Tower Research Capital LLC

(0%)

since

2025/03/31

17.

Virtu Financial LLC

(0%)

since

2025/06/30

18.

TWO SIGMA SECURITIES, LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

-0.75

Latest Release

Date

2025-09-30

EPS Actual

-0.33

EPS Estimate

-0.79

EPS Difference

0.46

Surprise Percent

58.2278%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Strong Net-Net(7.5)
Quality
Low Quality Business(2.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.